RPI ID: 2021-049-201
Innovation Summary: A nasal spray formulation combines pentosan polysulfate and mucopolysaccharide polysulfate to prevent and treat COVID-19. The compounds act as viral entry inhibitors by blocking spike protein binding to host cells. The spray is designed for prophylactic and therapeutic use, with potential for broad-spectrum antiviral activity. It is administered intranasally for localized action.
Challenges / Opportunities: Respiratory viruses like SARS-CoV-2 require effective barrier-based interventions. This invention offers a non-invasive, locally acting solution that can be used in high-risk environments. It supports rapid deployment and self-administration. The formulation may be adapted for other respiratory pathogens.
Key Benefits / Advantages: ✔ Intranasal antiviral delivery ✔ Spike protein inhibition ✔ Prophylactic and therapeutic use ✔ Non-invasive administration ✔ Broad-spectrum potential
Applications: • COVID-19 prevention • Respiratory virus treatment • Public health interventions
Keywords: #nasalspray #covid19 #antiviraltherapy #pentosanpolysulfate #mucopolysaccharide #respiratoryhealth
Intellectual Property: US Application 18/237624 US20240066051A1 filed 24-Aug-2023